On L1 Attrition and Prosody in Pronominal Anaphora Resolution

This thesis is a collection of four studies on pronominal anaphora resolution with a focus on first language (L1) attrition and prosody. In Study I, we explored the temporariness of attrition effects on anaphora resolution in L1 Italian speakers who moved to Sweden after puberty (i.e., late bilinguals). An experimental group of 20 late Italian-Swedish bilinguals and a control group of 21 Italian monolinguals completed a self-paced interpretation task twice, and we measured response preferences and response times. In Study II, we investigated how L1 Italian and L1 Swedish speakers use pause features and prominence cues to resolve globally ambiguous anaphora sentences, and whether their patterns in the use of prosody mirror the divergent coreference patterns in the two languages. 28 L1 Italian speakers and 28 L1 Swedish speakers completed a speech production task, in which we analyzed the inter-clausal pause length and the pronoun’s degree of prosodic prominence, and a control interpretation task, in which we considered response preferences. Study III represents a continuation of Study II, since we examined a group of 18 late Italian-Swedish bilinguals, who completed the same experimental tasks of Study II. Study IV is a theoretical investigation, in which we discussed previous inconsistent findings on anaphora resolution in light of the interplay between hierarchical structure and linear order of a sentence. The results of the four studies suggest, first, that anaphora resolution may also affect null pronouns, and that task-learning effects should be taken into account for further research on L1 re-immersion. Second, they suggest that inter-clausal pause and prosodic prominence of pronouns are likely to break the canonical coreference pattern, both in a null subject language and in a non-null subject language. Third, the findings also reveal that L1 attrition affects prominence patterns and pause features in pronoun resolution. In particular, the longer the residence in the foreign language (FL) environment, the higher the probability that late bilinguals adapt to the FL patterns when they use prosody to resolve anaphora sentences. Fourth, both monolinguals and bilinguals are sensitive to the interplay between hierarchical structure and linear order of anaphora. However, they employ different strategies to interpret an anaphora sentence, in which hierarchical structure and linear order favor different antecedents. The implications of the findings are discussed in light of the role of processing and cross-linguistic influence (CLI) in L1 attrition, as well as in light of the use of prosodic cues to resolve an anaphoric reference, both in relation to the Null Subject Parameter and in relation to L1 attrition

AD HOC SURVEYS: HOW TO MEASURE AND REPORT QUALITY METHODS

Surveys need a clear report on adopted quality methods to support surveillance, research and to implement evidence-based health policies. Aim of this report is to provide a simple and practical tool to those interested in survey, like HIS or HES , suggesting the different aspects of the quality to be controlled. These are crucial to generate useful and reliable results that can help the monitoring of health policy in Europe. Starting from the wide literature available in the field, the various quality dimensions that should be documented in a quality report and support the published results are briefly presented. In this paper, the six dimensions of the quality are analysed, as well as the different steps necessary to implement a survey, with particular attention to the quality and taking account of the remarkable expertise in the field. Before starting the survey, as known, the planning of specific steps is required. Moreover, to improve quality, training and testing of personnel involved in the different sets (organization, data collection, data processing, and statistical analysis) are fundamental. The methods used and the results obtained need to be published

The Outcome of Technical Intraoperative Complications Occurring in Standard Aortic Endovascular Repair

Background Technical intraoperative complications (TICs) may occur during standard endovascular repair (EVAR) with possible effects on the outcome. This study evaluates the early and midterm effects of TICs on EVARs. Methods All EVARs (from 2012 to 2016) were analyzed to identify all TICs: (1) endoluminal defects (stenosis, dissection, rupture, compression of native arteries, or endograft); (2) type I-III endoleaks; (3) unplanned artery coverage; and (4) surgical access complications. Follow-up was performed by Doppler ultrasound/ontrast enhanced ultrasound/computed tomography scan at yearly intervals. The outcome was compared with that of uneventful cases (UCs) through Fisher's exact test and Kaplan-Maier curve. Results TICs occurred in 68 (18%) of 377 patients undergoing EVAR. Thirty-two endoluminal defects were relined endovascularly; 24 type I-III endoleaks were treated with cuff deployment/forced ballooning (23) and surgical conversion (1); 3 of 8 unplanned artery coverages were revascularized (2 renal and 1 hypogastric); 5 hypogastric coverages had an unsuccessful correction; and 4 access artery injuries were repaired. Although fluoroscopy time and contrast usage were significantly higher in the TIC group than those in the UC group (309 cases), 30-day outcome was similar for death (1.4% TIC vs 0% UC, P = 0.18), reintervention (0% TIC vs 0.3% UC, P = 1), type I-III endoleak (0% TIC vs 0.9% UC, P = 1), steno-occlusions (0% TIC vs 0.3% UC, P = 1), buttock claudication, and renal failure (0% in both groups). At 24 months, TIC and UC groups had similar survival (91.7 ± 8% vs 96.2 ± 2.1%, P = 0.5), freedom from reintervention (81.4 ± 9.9% vs 96 ± 2.2%, P = 0.49), overall complication rate (13.4 ± 7.6% vs 11.4 ± 3.5%, P = 0.49), type I-III endoleak (11.2 ± 7.5% vs 7 ± 2.9%, P = 0.8), buttock claudication (0% vs 2 ± 2% P = 0.6), and hemodialysis (0% in both). Midterm iliac leg occlusion was significantly higher in the TIC group (26.9 ± 12.3% vs 3 ± 2.1%, P = 0.01). Conclusion TICs may affect several aspects during EVAR, leading to the necessity of adjunctive maneuvers, which have no impact on early outcome but may cause an increased rate of midterm iliac leg occlusion

Lamin A/C sustains PcG protein architecture, maintaining transcriptional repression at target genes

Beyond its role in providing structure to the nuclear envelope, lamin A/C is involved in transcriptional regulation. However, its cross talk with epigenetic factors--and how this cross talk influences physiological processes--is still unexplored. Key epigenetic regulators of development and differentiation are the Polycomb group (PcG) of proteins, organized in the nucleus as microscopically visible foci. Here, we show that lamin A/C is evolutionarily required for correct PcG protein nuclear compartmentalization. Confocal microscopy supported by new algorithms for image analysis reveals that lamin A/C knock-down leads to PcG protein foci disassembly and PcG protein dispersion. This causes detachment from chromatin and defects in PcG protein-mediated higher-order structures, thereby leading to impaired PcG protein repressive functions. Using myogenic differentiation as a model, we found that reduced levels of lamin A/C at the onset of differentiation led to an anticipation of the myogenic program because of an alteration of PcG protein-mediated transcriptional repression. Collectively, our results indicate that lamin A/C can modulate transcription through the regulation of PcG protein epigenetic factors

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

Introduction: Brodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab in a real-life setting are still limited

Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study—IL PSO (Italian landscape psoriasis)

Background: Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin-23. It is approved for treatment of moderate– severe chronic plaque psoriasis. Objectives: We conducted a 52-week retrospective study to assess the effectiveness and safety of tildrakizumab in a real-life setting. Methods: Our retrospective study included 237 consecutive adults with moderateto-severe plaque psoriasis, enrolled in 10 different Italian centres, treated with tildrakizumab up to Week 52. Patient characteristics, comorbidities, previous treatmentsand the PASI (Psoriasis Area and Severity Index) score at each visit (baseline, Week 16, Week 28 and Week 52) were retrieved from the electronic medical records. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI with respect to baseline PASI were registered. Results: At Week 52, 90.91%, 73.55% and 58.68% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. An absolute PASI≤2 was reached by 85.95% at Week 52. Compared with Phase 3 clinical trials, we observed similar rates of PASI 75/90 responses and higher percentages of patients achieving PASI 100. Patients who had not responded to previous biologic treatments and patients with cardio-metabolic comorbidities were significantly more likely to achieve PASI 100 at Week 28 and PASI 90 at Week 52. The higher body mass index did not interfere with the odds of reaching PASI 75/90/100 at each time point. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment because of adverse events. Conclusion: Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in ‘real-life’ clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52